On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


VOD First Mover The Movie Studio Inc. (MVES) Files Application for Registered Trademark with the U.S. Patent and Trademark Office

  • MVES files application to patent its name, insignia, phrase and logo with U.S. Patent and Trademark Office
  • MVES monetizes movies, licensed content through advertiser on demand (“AVOD”) and subscription video on demand (“SVOD”) services
  • VOD industry expected to reach $86 million by 2025, growing at CAGR of 10.7% from 2020-2025

As more entertainment consumers cut the cord and gravitate to Video on Demand (“VOD”), The Movie Studio (OTC: MVES), a vertically integrated motion picture production and distribution company, continues to make bold moves to solidify its industry position – this time by filing an application to trademark its name with the U.S. Patent and Trademark Office. The move represents a logical next step for MVES as it seeks to protect its recognizable name, insignia, phrase and logo in preparation for the release of its new app that will showcase its motion picture content to a loyal global audience.

Both MVES’s brand and logo are recognized assets that widely communicate the company’s brand, products and services across the VOD, smart TV and blockchain-based digital film marketplaces. The company’s Movie Studio app features both advertiser on demand (“AVOD”) and subscription video on demand (“SVOD”) services that monetize its movies and licensed content. Soon to be integrated with eStreamTV, a provider of integrated advertising on television platforms, MVES’s disruptive technology breaks boundaries initially set by the legacy advertising model of the industry, giving the company an edge in content distribution and monetization.

“The pending trademark of ‘The Movie Studio’ fulfills our objective as we enter the second tier of the digital revolution,” stated president and CEO Gordon Scott Venters in recent statements (http://ibn.fm/vjBUW). “We have confidence in the value proposition of the brand and our acceleration into the exploding digital motion picture universe.”

Besides its distinctive revenue model, MVES has also innovated its marketing strategy through the app’s MovieSodes feature that displays partial distribution of its productions. Through the use of a fractured manufacturing process, the ten-minute episodes will be filmed intermittently, featuring short inventive clips of content that are then joined at the end into a feature movie for global distribution. Along with creating excitement around the film, the Moviesodes component also inspires user engagement through an additional feature that lets users submit audition clips that are sent to producers for possible participation in upcoming productions.

MVES’s disruptive revenue, marketing and production strategies position the company as a first mover in the rapidly-expanding VOD space, expected to show an annual growth rate of 10.7% between 2020 and 2025, resulting in a projected market volume of nearly $86 million by 2025 (http://ibn.fm/r2IJs). The trend is expected to continue as more televisions are manufactured with built-in apps that enable over-the-top (“OTT”) platforms, further influenced by the closure of movie theatres and other public entertainment spaces that forcibly alter the habits of consumers.

MVES operates with a core mission of creating shareholder value through motion picture production and aggregation, diversified revenue models, and marketing strategies that attract and engage legions of loyal fans. With world events rapidly shifting consumer preferences towards VOD, MVES is in a favorable position to emerge as a unique – and soon to be patented – brand within the VOD industry.

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

September 25, 2020

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, […]

Rotate your device 90° to view site.